1082 / 1224
Conclusions
•
Extreme hypo with BT bears large dosimetric uncertainties, and benefits
from high target dose per fraction: flat part of dose response curve is less
sensitive to uncertainties in dose
•
Future development of BT fractionation schemes should take into account
➢
Existing/missing knowledge about dose response relationships
▪
For target and OARs!
➢
Existing/missing knowledge about uncertainty budget of the specific treatment
technique and workflow
➢
All these combined will help to improve safety of predicting the optimal
therapeutic window